AstraZeneca has consistently been at the forefront of biomarker-driven precision medicine by working with leading diagnostic partners to develop tests, including the analysis of gene mutations and protein expression. Biomarker testing may improve cancer care by helping identify patients who may be eligible for appropriate treatment options.

Biomarker testing is helping to advance progress in cancer treatment as one of several factors that influence therapy selection. Yet, many patients are still not being tested for biomarkers that could identify them as candidates for targeted treatment options.

AstraZeneca seeks to empower physicians to make informed treatment decisions by applying cutting-edge diagnostic tools to identify appropriate patients for targeted treatments. To learn more about our commitment to personalised healthcare, please visit: goto.az/testing

References:

Coloured circles indicate biomarkers of focus for AstraZeneca/MedImmune
Yellow icons indicate biomarker tests available in certain tumour types

Please note this is a representative list of biomarkers that inform clinical decisions in various tumors and is not comprehensive.

© AstraZeneca. All rights reserved